Pharmaceutical plant in Almaty sets up production of drugs for COVID-19 treatment
Kazakhstan started manufacturing the ‘Favipiravir’ drug to treat the novel coronavirus. The antiviral drug, which has been effectively used in fight against COVID-19 in Japan, China and several other countries, is now being produced at a pharmaceutical plant in Almaty. Currently, the domestic drug manufacturing company has begun the drug registration process. After that, the pharmaceutical company intends to begin supplying the domestic market with Favipiravir. Already this fall, the antiviral medication will be delivered to hospitals in the country. In addition, the pharmaceutical manufacturer boosted up the production of ‘Azithromycin’. Within the past month alone, demand for this medicine grew nearly five or six times.
“As for Azithromycin, we produced 600,000 packages in the last six months, but now within the next month alone we plan to manufacture as many as 300,000 packages. We just had a meeting with Mayor of Almaty. The stabilization fund is being created in the city. We will also be supplying our pharmaceutical products there. I hope that the current problem will be solved in the next five or 10 days due to the efforts of medical specialists and pharmacists,” said Chief Executive Officer of the pharmaceutical plant Svetlana Kiel.